Bristol Myers Squibb (NYSE: BMY) has posted better-than-expected second-quarter 2025 results, driven by strong sales of its ...

Endometriosis remains a complex challenge for patients and drug developers, with GlobalData highlighting five major gaps ...

Shares in French pharma major Sanofi were 6% lower late Thursday after the presentation of the company’s second quarter ...

Shares of US pharma major AbbVie were up 6.1% at $200.96 in pre-market activity, as it announced second-quarter 2025 ...

The hidradenitis suppurativa (HS) market across the seven major pharmaceutical markets (7MM) is projected to grow from $1.84 ...

As Indian drug manufacturers cry foul over the surge of cheap Chinese pharmaceutical raw material imports, the Indian ...

Japan’s Eisai and US biotech major Biogen have announced that the latest findings demonstrating the benefits of continuous ...

US pharma major AbbVie is considering a $1-billion acquisition of Gilgamesh Pharmaceuticals, Bloomberg News reported on Wednesday, citing people familiar with the matter.

Ipsen (Euronext: IPN) has reported second-quarter sales of 901 million euros ($980 million), up 8% from the same period a ...

UCB, Belgium’s largest drugmaker, today released financial results for first half 2025, showing total revenue in increased to ...

Moderna (Nasdaq: MRNA) has secured European clearance for its latest version of Spikevax (elasomeran) for individuals aged ...

Swedish biotech Oncopeptides (Nasdaq Stockholm: ONCO) has entered into a partnership with Spanish pharmaceutical broker SD ...